Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLA bevacizumab biosimilar trial in advanced non-squamous NSCLC
2017-001769-26Phase 3Completed
- Sponsor
- mAbxience
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Non-small cell lung cancer (NS-NSCLC) comparing MB02 + carboplatin + paclitaxel with Avastin + carboplatin + paclitaxel (2 arms). Primary endpoint: Objective Response Rate. Started Sep 2017; status: completed.
02
Drugs
bevacizumab MB02bevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2017-001769-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001769-26.